Project Grant RF1NS133979
Award Date
8/1/23
Completion Date
7/31/26
Dollars Obligated
$2.2M
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This $406,260 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program will support research to investigate the spread of alpha-synuclein protein aggregates, which is a key mechanism believed to underlie the onset and progression of Parkinson's disease and related dementias. The research aims to characterize the aggregation states of...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, will provide $414,191 to Drexel University from August 1, 2024 to July 31, 2026. The research aims to investigate how alpha-synuclein (α-syn) protein fibril conformations influence the emergence of distinct pathologies in synucleinopathies, including Lewy body dementia,...
This $682,493 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports research to elucidate the role of aberrant histone acetylation in the pathogenesis of Parkinson's disease (PD) and related synucleinopathies. The research involves using a human pluripotent stem cell-based discovery platform to investigate the impact of...
This $2,280,379 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to develop novel nanobody-based agents that can target intracellular and extracellular alpha-synuclein aggregates. The goal is to block the prion-like propagation of alpha-synuclein pathology, which is associated with Lewy body dementias including...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $223,750 to Brigham & Women's Hospital Inc. to conduct research on distinguishing normal and abnormal forms of the protein alpha-synuclein (α-synuclein) and their impact on synaptic transmission. The research aims to elucidate the differences in the biological properties of normal and pathological phosphorylation of α-synuclein at serine 129 (pS129) in order to refine pS129 as a marker...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will fund research to investigate the influence of neuromelanin accumulation on dopaminergic neurons in Parkinson's disease. The award of $616,200.00 will support experiments to delineate the anatomical, behavioral, electrophysiological, and molecular effects of progressive neuromelanin...
This R01 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the federal Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) grant program, provides $655,329 to support research on the role of the GPNMB gene in the pathogenesis of Parkinson's disease, Lewy body dementia, and related synucleinopathies. The research aims to use CRISPR/Cas9 genome editing in human pluripotent stem cells to identify causal genetic...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is focused on investigating the origin and pathogenic properties of alpha-synuclein strains found in the plasma of individuals with Parkinson's disease (PD). The $231,255 award, effective July 15, 2024 through June 30, 2029, will support the following key research activities:...
This three-year, $3.4 million Project Grant from the National Institute on Aging will support research into the combinatorial effects of post-translational modifications on alpha-synuclein structure, function, and aggregation. The Trustees of the University of Pennsylvania will investigate how multiple simultaneous modifications to alpha-synuclein impact its interactions with lipid bilayers, self-association kinetics, aggregate structural features, internalization by neurons, and seeded...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $1,386,000.00 to the Augusta University Research Institute, Inc. over a 3-year period from September 2024 to August 2027. The grant is intended to support a comprehensive investigation into the mechanisms by which the protein alpha-synuclein may spread from the gastrointestinal tract to the brain, leading to neurodegeneration and...